Fig. 2: Comparison of neutralizing antibody response among different clinical spectra of COVID-19 convalescents.
a, Comparison of the available peak levels of anti-RBD IgG for the severe (n = 13), mild (n = 22) and asymptomatic groups (n = 11). P values: severe vs mild, 0.3891; severe vs asymptomatic, 0.0012; mild vs asymptomatic, 0.0218. Dotted lines indicate the limit of detection. b, Comparison of the available peak MN titres for the severe (n = 14), mild (n = 23) and asymptomatic groups (n = 11). P values: severe vs mild, 0.122; severe vs asymptomatic, <0.0001; mild vs asymptomatic, 0.0051. c, Comparison of the current levels of anti-RBD IgG for the severe (n = 13), mild (n = 22) and asymptomatic groups (n = 11). P values: severe vs mild, 0.0061; severe vs asymptomatic, <0.0001; mild vs asymptomatic, 0.0039. d, Comparison of the current MN titres for the severe (n = 14), mild (n = 23) and asymptomatic groups (n = 11). P values: severe vs mild, 0.0405; severe vs asymptomatic, 0.0014; mild vs asymptomatic, 0.0714. Specimens with MN titres <10 were assigned a value of 5. Statistical significance was determined using two-sided Mann–Whitney U-test. *P < 0.05, **P < 0.01, ***P < 0.001. The line and error bar represent the mean and standard deviation for the anti-RBD IgG, and geometric mean titre and standard deviation for the MN titres. e,f, Distribution of the available peak and current MN titres for severe, mild and asymptomatic groups.
